Literature DB >> 3948173

Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products.

N E Davidson, D A Bronzert, P Chambon, E P Gelmann, M E Lippman.   

Abstract

Two variants of the human estrogen-responsive breast cancer cell line MCF-7, were utilized to study the expression of an estrogen-induced gene, pS2, and an estrogen-induced Mr 52,000 protein. One variant cell line, I13, is growth inhibited after chronic exposure to estrogen. Both the pS2 gene product and the Mr 52,000 protein were produced at maximal levels at a time when I13 growth was inhibited by estrogen. The variant cell line, LY2, selected for its resistance to the growth-inhibitory effects of the antiestrogen, LY117018, grew normally in the presence of this drug, although both pS2 expression and Mr 52,000 protein production were inhibited. These results confirm that the pS2 gene and Mr 52,000 protein are estrogen-regulated elements, but the lack of correlation between their activities and variant cell growth suggests that they are not major autocrine growth-stimulatory agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948173

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.

Authors:  Tissa T Manavalan; Yun Teng; Savitri N Appana; Susmita Datta; Theodore S Kalbfleisch; Yong Li; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2011-09-10       Impact factor: 8.679

2.  Cadmium promotes breast cancer cell proliferation by potentiating the interaction between ERalpha and c-Jun.

Authors:  Christina L Siewit; Bridget Gengler; Esera Vegas; Rachel Puckett; Maggie C Louie
Journal:  Mol Endocrinol       Date:  2010-03-10

3.  8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer.

Authors:  M E Lippman; R B Dickson; S Bates; C Knabbe; K Huff; S Swain; M McManaway; D Bronzert; A Kasid; E P Gelmann
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

4.  Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

Authors:  V Cavailles; P Augereau; M Garcia; H Rochefort
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

Review 5.  Antiestrogen resistance in ER positive breast cancer cells.

Authors:  S Paik; D P Hartmann; R B Dickson; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 6.  Mitogenic regulation of normal and malignant breast epithelium.

Authors:  M E Lippman; R B Dickson
Journal:  Yale J Biol Med       Date:  1989 Sep-Oct

7.  SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo.

Authors:  Y Berthois; B Bourrié; S Galiègue; H Vidal; P Carayon; P M Martin; P Casellas
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

8.  β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression.

Authors:  Zainab M T Jafaar; Lacey M Litchfield; Margarita M Ivanova; Brandie N Radde; Numan Al-Rayyan; Carolyn M Klinge
Journal:  Int J Oncol       Date:  2014-02-10       Impact factor: 5.650

9.  HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.

Authors:  Belinda J Petri; Kellianne M Piell; Gordon C South Whitt; Ali E Wilt; Claire C Poulton; Norman L Lehman; Brian F Clem; Matthew A Nystoriak; Marcin Wysoczynski; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2021-07-14       Impact factor: 9.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.